By Nigam Arora & Dr. Natasha Arora
Signal(s) to enter, add, reduce, exit, hold or change.
Here are the key points on January Effect trades:
- There were five fills.
- Four trades are nicely profitable. The fifth trade is at a slight profit to break even, depending upon how it was bought.
- Since gains have occurred over a short period of time, annualized gains become rather large.
- The maximum annualized gain on a position is 843%.
What To Do Now
These stocks have a lot of room to run. If the market rallies, four of the stocks listed below can easily double or even triple from here. The fifth, GTLS, can gain 30% – 40% from here. On the other hand, these are long duration stocks. Please listen to the podcast titled “Be Careful With Popular Long Duration Stocks.” If the market starts viciously selling long duration stocks again, all the gains will be quickly lost.
What to do now depends on your personal preference due to high market volatility. Here are helpful guidelines.
Desktop Metal
DM is a 3D printing company producing high grade advanced materials.
The gain on DM is 46.2%. This translates to 843% annualized gain. DM closed at $1.71.
Consider taking partial or full profits based on personal preference. If taking partial profits, move the stop to 🔒 (To see the locked content, please take a 30 day free trial) on the remaining quantity.
Bionano Genomics
BNGO provides products and services for thorough analysis of the genome.
The gain on BNGO is 31.9%. This translates to 647% annualized gain. BNGO closed at $1.82.
Consider taking partial or full profits based on personal preference. If taking partial profits, move the stop to 🔒 on the remaining quantity.
Aurora Innovation
AUR is developing self-driving technology.
The gain on AUR is 17.1%. This translates to 347% annualized gain. AUR closed at $1.30.
Consider taking partial or full profits based on personal preference. If taking partial profits, move the stop to 🔒 on the remaining quantity.
Chart Industries
GTLS makes, sells, and services equipment for the liquid gas supply chain. GTLS equipment is also being used for the new hydrogen economy.
The gain on GTLS is 15%. This translates to 166% annualized gain. GTLS closed at $133.71.
Consider taking partial or full profits based on personal preference. If taking partial profits, move the stop to 🔒 on the remaining quantity.
Cano Health
CANO provides online healthcare to seniors. CANO is a buyout target, but there is also the risk of the company running out of cash and filing for bankruptcy. If the company is able to raise adequate cash, it can potentially ultimately be bought out even over $10.
Considering the high risk reward nature of this stock, what to do now entirely comes down to personal preference. One good option to consider is to reduce the quantity and put a stop on the rest. However, you need to be aware that if there is a gap down, the stop may not protect you. The stop zone is 🔒.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
